[
    [
        {
            "time": "2018-03-05",
            "original_text": "Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy",
            "features": {
                "keywords": [
                    "Gilead",
                    "Positive Data",
                    "HIV Drugs",
                    "Biktarvy",
                    "Descovy"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2019-02-15",
            "original_text": "How Novartis Is Transforming Its Structure in 2019",
            "features": {
                "keywords": [
                    "Novartis",
                    "Transforming",
                    "Structure"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-04-10",
            "original_text": "Dutch join backlash at expensive drugs by making their own",
            "features": {
                "keywords": [
                    "Dutch",
                    "backlash",
                    "expensive drugs",
                    "own production"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 4,
                "Headline_Structure": 5,
                "Source_Recency": 4
            }
        }
    ]
]